Literature DB >> 21705419

Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Shanshan Huang1, Joseph J Ling, Su Yang, Xiao-Jiang Li, Shihua Li.   

Abstract

The polyglutamine diseases consist of nine neurodegenerative disorders including spinocerebellar ataxia type 17 that is caused by a polyglutamine tract expansion in the TATA box-binding protein. In all polyglutamine diseases, polyglutamine-expanded proteins are ubiquitously expressed throughout the body but cause selective neurodegeneration. Understanding the specific effects of polyglutamine-expanded proteins, when expressed at the endogenous levels, in neurons is important for unravelling the pathogenesis of polyglutamine diseases. However, addressing this important issue using mouse models that either overly or ubiquitously express mutant polyglutamine proteins in the brain and body has proved difficult. To investigate the pathogenesis of spinocerebellar ataxia 17, we generated a conditional knock-in mouse model that expresses one copy of the mutant TATA box-binding protein gene, which encodes a 105-glutamine repeat, selectively in neuronal cells at the endogenous level. Neuronal expression of mutant TATA box-binding protein causes age-dependent neurological symptoms in mice and the degeneration of cerebellar Purkinje cells. Mutant TATA box-binding protein binds more tightly to the transcription factor nuclear factor-Y, inhibits its association with the chaperone protein promoter, as well as the promoter activity and reduces the expression of the chaperones Hsp70, Hsp25 and HspA5, and their response to stress. These findings demonstrate how mutant TATA box-binding protein at the endogenous level affects neuronal function, with important implications for the pathogenesis and treatment of polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705419      PMCID: PMC3122377          DOI: 10.1093/brain/awr146

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  55 in total

1.  Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.

Authors:  Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

2.  Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene.

Authors:  Jiangqin Zhao; Alan Bilsland; Stacey F Hoare; W Nicol Keith
Journal:  FEBS Lett       Date:  2003-02-11       Impact factor: 4.124

Review 3.  Transcriptional regulation of cellular ageing by the CCAAT box-binding factor CBF/NF-Y.

Authors:  Koozi Matuoka; Kuang Yu Chen
Journal:  Ageing Res Rev       Date:  2002-09       Impact factor: 10.895

Review 4.  Mouse models of Huntington's disease.

Authors:  Liliana B Menalled; Marie-Françoise Chesselet
Journal:  Trends Pharmacol Sci       Date:  2002-01       Impact factor: 14.819

5.  RNA polymerase II transcription in murine cells lacking the TATA binding protein.

Authors:  Igor Martianov; Stephane Viville; Irwin Davidson
Journal:  Science       Date:  2002-11-01       Impact factor: 47.728

6.  Interaction of Huntington disease protein with transcriptional activator Sp1.

Authors:  Shi-Hua Li; Anna L Cheng; Hui Zhou; Suzanne Lam; Manjula Rao; He Li; Xiao-Jiang Li
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

7.  SCA17 caused by homozygous repeat expansion in TBP due to partial isodisomy 6.

Authors:  C H Zühlke; M Spranger; S Spranger; R Voigt; M Lanz; U Gehlken; F Hinrichs; E Schwinger
Journal:  Eur J Hum Genet       Date:  2003-08       Impact factor: 4.246

8.  Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17).

Authors:  Arndt Rolfs; Arnulf H Koeppen; Ingrid Bauer; Peter Bauer; Sven Buhlmann; Helge Topka; Ludger Schöls; Olaf Riess
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

9.  Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

Authors:  Theresa M Ballard; Meike Pauly-Evers; Guy A Higgins; Abdel-Mouttalib Ouagazzal; Vincent Mutel; Edilio Borroni; John A Kemp; Horst Bluethmann; James N C Kew
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

Review 10.  Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Authors:  Lauren S Havel; Shihua Li; Xiao-Jiang Li
Journal:  Mol Brain       Date:  2009-07-03       Impact factor: 4.041

View more
  33 in total

1.  Role of Mutant TBP in Regulation of Myogenesis on Muscle Satellite Cells.

Authors:  Dong-Ming Zhao; Sui-Qiang Zhu; Fu-Rong Wang; Shan-Shan Huang
Journal:  Curr Med Sci       Date:  2019-10-14

Review 2.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 3.  NF-Y (CBF) regulation in specific cell types and mouse models.

Authors:  Sankar N Maity
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2016-11-02       Impact factor: 4.490

Review 4.  The biology of proteostasis in aging and disease.

Authors:  Johnathan Labbadia; Richard I Morimoto
Journal:  Annu Rev Biochem       Date:  2015-03-12       Impact factor: 23.643

Review 5.  Genetically modified rodent models of SCA17.

Authors:  Yiting Cui; Su Yang; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci Res       Date:  2016-11-18       Impact factor: 4.164

6.  Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Authors:  Yang Yang; Su Yang; Jifeng Guo; Yiting Cui; Beisha Tang; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2017-08-18       Impact factor: 6.167

7.  Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice.

Authors:  Shanshan Huang; Su Yang; Jifeng Guo; Sen Yan; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Novel TTC19 mutation in a family with severe psychiatric manifestations and complex III deficiency.

Authors:  Célia Nogueira; José Barros; Maria José Sá; Luísa Azevedo; Ricardo Taipa; Alessandra Torraco; Maria Chiara Meschini; Daniela Verrigni; Claudia Nesti; Teresa Rizza; João Teixeira; Rosalba Carrozzo; Manuel Melo Pires; Laura Vilarinho; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2013-03-28       Impact factor: 2.660

10.  Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice.

Authors:  Su Yang; Shanshan Huang; Marta A Gaertig; Xiao-Jiang Li; Shihua Li
Journal:  Neuron       Date:  2014-01-22       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.